An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 13, Issue 5, Pages 394-407
Publisher
Wiley
Online
2011-01-06
DOI
10.1111/j.1463-1326.2011.01357.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
- (2013) Helena Rodbard et al. Endocrine Practice
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis
- (2010) R. Garg et al. DIABETES CARE
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
- (2010) J. B. Buse et al. DIABETES CARE
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes
- (2010) C. J. Girman et al. DIABETES OBESITY & METABOLISM
- Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
- (2010) Wolfgang Glaesner et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study1,2
- (2010) R. Ratner et al. DIABETIC MEDICINE
- Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
- (2010) G. Schernthaner et al. DIABETOLOGIA
- Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
- (2010) R. A. DeFronzo DIABETOLOGIA
- Taspoglutide, an Analog of Human Glucagon-Like Peptide-1 with Enhanced Stability andin VivoPotency
- (2010) Elena Sebokova et al. ENDOCRINOLOGY
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
- (2010) Mary Parks et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events
- (2009) Bo Ahrén BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results
- (2009) Sten Madsbad BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
- (2009) David J Grieve et al. BRITISH JOURNAL OF PHARMACOLOGY
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
- (2009) David D. Dore et al. CURRENT MEDICAL RESEARCH AND OPINION
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
- (2009) J. Rosenstock et al. DIABETES CARE
- Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study
- (2009) M. A. Nauck et al. DIABETES CARE
- Incretin-Based Therapies: Viewpoints on the way to consensus
- (2009) Michael. A. Nauck et al. DIABETES CARE
- Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
- (2009) M. A. Bush et al. DIABETES OBESITY & METABOLISM
- Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily
- (2009) J. H. Best et al. DIABETIC MEDICINE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Exenatide once weekly for the treatment of type 2 diabetes
- (2009) James Malone et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials
- (2008) Sten Madsbad et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2008) D. M. Nathan et al. DIABETES CARE
- An Albumin-Exendin-4 Conjugate Engages Central and Peripheral Circuits Regulating Murine Energy and Glucose Homeostasis
- (2008) Laurie L. Baggio et al. GASTROENTEROLOGY
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Treatment of type 2 diabetes with incretin-based therapies
- (2008) Sten Madsbad LANCET
- Glucagon-like peptide-1, glucose homeostasis and diabetes
- (2008) Jens J. Holst et al. TRENDS IN MOLECULAR MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started